Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Loibl, Sibylle, Huang, Chiun-Sheng, Mano, Max S., Mamounas, Eleftherios P., Geyer, Charles E., Untch, Michael, Thery, Jean-Christophe, Schwaner, Ingo, Limentani, Steven, Loman, Niklas, Lübbe, Kristina, Chang, Jenny C., Hatschek, Thomas, Tesarowski, David, Song, Chunyan, Lysbet de Haas, Sanne, Boulet, Thomas, Lambertini, Chiara, Wolmark, Norman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482917/
https://www.ncbi.nlm.nih.gov/pubmed/36117201
http://dx.doi.org/10.1038/s41523-022-00477-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482917/
https://www.ncbi.nlm.nih.gov/pubmed/36117201
http://dx.doi.org/10.1038/s41523-022-00477-z

Ejemplares similares